ArticleFrontiers in endocrinology2026
Machine learning-based prediction of NAFLD in patients with type 2 diabetes using routine clinical and biochemical indicators.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to develop and evaluate machine learning (ML) models for predicting non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM) using readily accessible clinical and biochemical indicators. Methods: A total of 2,459 patients with T2DM were enrolled in this cross-sectional study. Eight ML algorithms, logistic regression (LG), k-nearest neighbors (k-NN), support vector machine (SVM), decision tree (DT), random forest (RF), gradient boosting machine (GBM), extreme gradient boosting (XGBoost), and naïve Bayes (NB), were developed to construct predictive models. Feature selection was performed using Boruta, recursive feature elimination, and LASSO regression. Model performance was assessed using several metrics, including the area under the receiver operating characteristic curve (AUC), accuracy, recall, F1 score, and decision curve analysis. Results: Among the study population, 1,309 individuals (53.23%) were diagnosed with NAFLD. Sixteen variables, including BMI, waist circumference, systolic blood pressure, triglycerides, HDL-C, ALT, GGT, bilirubin fractions, albumin, BUN, GFR, fasting insulin, RBC, and hemoglobin, were selected as key predictors. The SVM model demonstrated the best overall performance, achieving an AUC of 0.920, accuracy of 0.839, and specificity of 0.898 in the training set, and an AUC of 0.833 and accuracy of 0.733 in the validation set. Decision curve analysis confirmed superior clinical utility of the SVM model compared with other algorithms. Conclusions: ML-based models, particularly the SVM algorithm, effectively predicted NAFLD among patients with T2DM using easily accessible clinical and biochemical indicators. These findings highlight the potential utility of ML-assisted screening tools for improving early identification and risk stratification of NAFLD in diabetic populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.